PMID- 27631214
OWN - NLM
STAT- MEDLINE
DCOM- 20170217
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 95
IP  - 37
DP  - 2016 Sep
TI  - Circulating biomarkers in acute myofascial pain: A case-control study.
PG  - e4650
LID - 10.1097/MD.0000000000004650 [doi]
LID - e4650
AB  - The aims of the present study were to compare levels of circulating inflammatory 
      biomarkers and growth factors between patients with myofascial pain syndrome 
      (MPS) and healthy control participants, and to assess the relationship among 
      inflammatory markers and growth factors in the two groups.Biomarkers levels were 
      assessed in patients (n = 37) with myofascial pain complaints recruited from the 
      hospital emergency department and non-MPS controls (n = 21), recruited via 
      advertisements in the hospital and community.Blood levels of the cytokines, 
      namely, interleukin-6 (IL-6), tumor necrosis factor (TNF), and interleukin-12 
      (IL-12), and the chemokine, namely, monocyte chemoattractant protein-1 (MCP-1), 
      macrophage-derived chemokine (MDC), eotaxin, granulocyte-macrophage 
      colony-stimulating factor (GM-CSF), interleukin-8 (IL-8), and macrophage 
      inflammatory proteins-1beta (MIP-1beta) were significantly higher in patients with MPS 
      than controls. The results of the growth factor analyses revealed significantly 
      higher levels of fibroblast growth factor-2 (FGF-2), platelet-derived growth 
      factor (PDGF), and vascular endothelial growth factor (VEGF) in MPS patients 
      versus controls. The pattern of correlation coefficients between cytokines and 
      growth factors differed considerably for MPS patients and controls with far fewer 
      significant positive coefficients observed in the controls. Serum inflammatory 
      and growth factor biomarkers were elevated in MPS patients.Inflammatory 
      biomarkers and growth factor levels may play an important role in the onset and 
      maintenance of MPS and therefore may be useful in the diagnosis and treatment of 
      MPS. Understanding the mechanisms of inflammation in MPS necessitates future 
      research.
FAU - Grosman-Rimon, Liza
AU  - Grosman-Rimon L
AD  - Toronto Rehabilitation Institute, University Health Network Department of 
      Anesthesia, University of Toronto McMaster University, Hamilton Department of 
      Anesthesia and Pain Management, Toronto General Hospital, University Health 
      Network Department of Psychology, York University Department of Medicine, 
      Division of Physical Medicine and Rehabilitation, University of Toronto, Toronto, 
      ON, Canada.
FAU - Parkinson, William
AU  - Parkinson W
FAU - Upadhye, Suneel
AU  - Upadhye S
FAU - Clarke, Hance
AU  - Clarke H
FAU - Katz, Joel
AU  - Katz J
FAU - Flannery, John
AU  - Flannery J
FAU - Peng, Philip
AU  - Peng P
FAU - Kumbhare, Dinesh
AU  - Kumbhare D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
SB  - IM
MH  - Adult
MH  - Biomarkers/*blood
MH  - Case-Control Studies
MH  - Cytokines/blood
MH  - Female
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins/blood
MH  - Male
MH  - Middle Aged
MH  - Myofascial Pain Syndromes/*blood
PMC - PMC5402557
COIS- The authors report no conflicts of interest.
EDAT- 2016/09/16 06:00
MHDA- 2017/02/18 06:00
PMCR- 2016/09/16
CRDT- 2016/09/16 06:00
PHST- 2016/09/16 06:00 [entrez]
PHST- 2016/09/16 06:00 [pubmed]
PHST- 2017/02/18 06:00 [medline]
PHST- 2016/09/16 00:00 [pmc-release]
AID - 00005792-201609130-00016 [pii]
AID - 10.1097/MD.0000000000004650 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2016 Sep;95(37):e4650. doi: 10.1097/MD.0000000000004650.